A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.

Intellia Therapeutics NTLA has made good progress with the advancement of its in vivo candidate, lonvo-z (or, NTLA-2002), ...

Former Horizon Discovery CEO Terry Pizzie has been appointed to a similar role with Cambridge based Broken String Biosciences ...

Bengaluru-based biotechnology startup CrisprBits Private Limited has raised USD 3 Million through founders, angels & family ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the most oversold biotech stocks to invest in. On November 11, Jones ...

CrisprBits has secured $3 Mn (INR 26.8 Cr) in a pre-Series A funding round led by Spectrum Impact and Rajendra Gogri's family ...

According to DataM Intelligence, the Regenerative Medicine Market Size reached USD48.45 billion in 2024 and is expected to ...

India could not take full advantage of cultivating GM crops. But the story is more encouraging in GE crops, where there is ...

Shares of Intellia Therapeutics NTLA have witnessed a sharp decline in the past month, primarily due to a regulatory setback ...

A breakthrough study has just supercharged Fusarium venenatum (the fungus used in mycoprotein products like Quorn), turning ...

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing ...

The new GE technology — for which the Indian Council of Agricultural Research (ICAR) has recently been granted a patent — ...